Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Tibotec Therapeutics, makers of prescription medication Intelence (etravirine) used to control HIV infection in adults, recently notified health care professionals that the medication has been linked to a rare but life-threatening skin condition known as Stevens Johnson Syndrome, SJS.

Early this year, Intelence was approved by the the Food and Drug Administration (FDA) for use in the treatment of HIV. At that time, data indicated a slight risk of SJS.

SJS, and its most severe form, toxic epidermal necrolysis, TEN, are identified by a rash on the skin that blisters over causing the skin to peel off in sheets. The condition is extremely painful and often requires hospitalization to treat the open wounds on the skin, mouth, eyes and other mucous membranes. Complications include infection, dehydration, vision problems, organ dysfunction and death.

Read the rest of this entry »

Drug maker Tibotec, which specializes in innovative therapeutic and diagnostic solutions for infectious diseases such as HIV/AIDS, is seeking approval from the FDA for its latest HIV treatment, Intelence, based on data from its phase-three studies of the drug when used in combination with other antiretroviral agents, according to a press release from Hays Pharma, a global pharmaceutical and biotech staffing and recruitment business.

Read the rest of this entry »